PentixaPharm gets 15M euros for radiopharmaceutical trials

2019 07 04 00 21 3668 Euros Bills 400

PentixaPharm has announced 15 million euros in funding to test a pair of radiopharmaceutical drugs to identify fast-progressing diseases, including cancer.

The series A funding round was led by Eckert Life Science Accelerator. The financing will help PentixaPharm test PentixaFor and PentixaTher, a pair of radiopharmaceuticals that target the chemokine receptor CXCR4.

The funding will specifically be used for a phase II trial of PentixaFor and a phase I trial of PentixaTher in central nervous system lymphoma. PentixaPharm will also use the funds to support proof-of-concept studies.

Page 1 of 551
Next Page